Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials

Research output: Contribution to journalReviewResearchpeer-review

  1. GLP-1 based therapies and disease course of inflammatory bowel disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Successful glucose lowering therapy triumphs in heart failure

    Research output: Contribution to journalComment/debateResearchpeer-review

  3. Implementation of indicator condition guided HIV testing still lagging behind the evidence

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Infographic. Benefits and harms of exercise therapy in people with multimorbidity

    Research output: Contribution to journalComment/debateResearchpeer-review

  2. Placebo response and effect in randomized clinical trials: meta-research with focus on contextual effects

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Background: The therapeutic role of methotrexate (MTX) for management of inflammatory bowel disease (IBD) remains unclear.

Methods: We systematically reviewed randomized, controlled trials (RCTs) of MTX for induction and maintenance of remission in IBD until January 2020 in accordance with PROSPERO protocol (#CRD42018115047). Relative risk (RR) of maintenance of remission, induction of remission, endoscopic disease activity, and adverse events were combined in a meta-analysis.

Findings: MTX monotherapy was not superior to placebo for induction of clinical remission in Crohn's disease (CD). However, MTX was superior to placebo in maintaining clinical remission of CD. Concomitant therapy with MTX and the TNF inhibitor infliximab (IFX) was not superior to IFX monotherapy in CD. In ulcerative colitis (UC), MTX monotherapy was not superior to placebo neither for induction of clinical remission, nor for maintenance of clinical remission. MTX did not result in superior endoscopic outcomes during induction or maintenance therapy compared with placebo. Regarding adverse events (AEs), our meta-analysis on CD studies showed a significantly higher risk of AEs when comparing MTX versus placebo in studies investigating induction of remission, but not in maintenance of remission. In UC, no such differences in AEs between MTX or placebo were observed.

Interpretation: Current data support the efficacy of parenteral MTX monotherapy for maintenance of clinical remission in CD. MTX is not confirmed to be effective for treatment of UC or for induction of remission in CD. No evidence supports concomitant MTX to improve efficacy of IFX (no other biologics investigated).

Original languageEnglish
JournalEClinicalMedicine
Volume20
Pages (from-to)100271
ISSN2589-5370
DOIs
Publication statusPublished - Mar 2020

ID: 62084409